Juan Martin-Liberal

List of Publications by Year
in descending order

33	990	686830 13	454577 30
papers	citations	h-index	g-index

34	34	34	1945
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncology, The, 2019, 20, 1109-1123.	5.1	193
2	Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunology, Immunotherapy, 2015, 64, 765-767.	2.0	129
3	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). Oncologist, 2018, 23, 1407-e136.	1.9	127
4	The expanding role of immunotherapy. Cancer Treatment Reviews, 2017, 54, 74-86.	3.4	100
5	Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma. Sarcoma, 2013, 2013, 1-6.	0.7	54
6	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology, 2021, 299, 109-119.	3.6	54
7	Prognostic score for patients with advanced melanoma treated with ipilimumab. European Journal of Cancer, 2015, 51, 2785-2791.	1.3	53
8	Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis. Clinical Sarcoma Research, 2013, 3, 13.	2.3	32
9	Safety of pembrolizumab for the treatment of melanoma. Expert Opinion on Drug Safety, 2015, 14, 957-964.	1.0	27
10	Immuno-Oncology: The Third Paradigm in Early Drug Development. Targeted Oncology, 2017, 12, 125-138.	1.7	22
11	Leiomyosarcoma: Principles of management. Intractable and Rare Diseases Research, 2013, 2, 127-9.	0.3	19
12	Prospects for MEK inhibitors for treating cancer. Expert Opinion on Drug Safety, 2014, 13, 483-495.	1.0	17
13	The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs. Trials, 2018, 19, 505.	0.7	17
14	Vemurafenib for the treatment of BRAF mutant metastatic melanoma. Future Oncology, 2015, 11, 579-589.	1.1	16
15	New RAF kinase inhibitors in cancer therapy. Expert Opinion on Pharmacotherapy, 2014, 15, 1235-1245.	0.9	13
16	First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma. Clinical Sarcoma Research, 2015, 5, 10.	2.3	13
17	First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours. British Journal of Cancer, 2020, 123, 1235-1243.	2.9	12
18	A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate.. Journal of Clinical Oncology, 2017, 35, 2570-2570.	0.8	12

#	Article	IF	Citations
19	Safety evaluation of trabectedin in treatment of soft-tissue sarcomas. Expert Opinion on Drug Safety, 2013, 12, 905-911.	1.0	11
20	Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. Targeted Oncology, 2018, 13, 81-87.	1.7	8
21	INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS3113-TPS3113.	0.8	8
22	Antiangiogenic approach in soft-tissue sarcomas. Expert Review of Anticancer Therapy, 2013, 13, 975-982.	1.1	7
23	New drugs in sarcomas. Expert Opinion on Pharmacotherapy, 2014, 15, 221-229.	0.9	7
24	Encorafenib plus binimetinib: an embarrassment of riches. Lancet Oncology, The, 2018, 19, 1263-1264.	5.1	7
25	Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma. Expert Opinion on Investigational Drugs, 2019, 28, 39-50.	1.9	7
26	Determining predictive factors for immune checkpointÂinhibitor toxicity: Response to Letter to the Editors â€œA case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcomeâ€• Cancer Immunology, Immunotherapy, 2016, 65, 769-770.	2.0	6
27	Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas?. Expert Review of Anticancer Therapy, 2015, 15, 257-259.	1.1	5
28	Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair. Oncogene, 2021, 40, 5042-5048.	2.6	2
29	Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: A report of the U.K. Managed Access Program.. Journal of Clinical Oncology, 2014, 32, 10551-10551.	0.8	2
30	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. European Journal of Cancer, 2021, 155, 168-178.	1.3	1
31	Serum troponin surveillance to predict cardiotoxicity of doxorubicin in adults with metastatic sarcoma.. Journal of Clinical Oncology, 2015, 33, e21516-e21516.	0.8	0
32	Outcomes of patients (pts) treated with novel immunotherapy (IT) agents in phase 1 clinical trials (Ph1-CT) at early lines for advanced disease.. Journal of Clinical Oncology, 2022, 40, 2581-2581.	0.8	0
33	Analysis of phase I clinical trials (Ph1-CT) new enrollment patterns in the immuno-oncology era.. Journal of Clinical Oncology, 2022, 40, e14549-e14549.	0.8	0